Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Well-differentiated Neuroendocrine Tumors”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Testing effectiveness (Phase 2)Study completedNCT03365791
What this trial is testing

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Who this might be right for
Small Cell Lung CancerGastric AdenocarcinomaEsophageal Adenocarcinoma+5 more
Novartis Pharmaceuticals 76
Testing effectiveness (Phase 2)Looking for participantsNCT07016230
What this trial is testing

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Who this might be right for
Metastatic/Locally Advanced Small-Cell Lung CancerMetastatic/Locally Advanced Poorly Differentiated NECMetastatic/Locally Advanced High-grade MTC
Gustave Roussy, Cancer Campus, Grand Paris
Testing effectiveness (Phase 2)Study completedNCT00953394
What this trial is testing

5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University of Turin, Italy 29
Early research (Phase 1)Ended earlyNCT05605522
What this trial is testing

[225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)Squamous Cell Carcinoma of Head and NeckColorectal Cancer+4 more
3B Pharmaceuticals GmbH 19
Post-approval studies (Phase 4)Study completedNCT01525550
What this trial is testing

The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Who this might be right for
Well-differentiated Pancreatic Neuroendocrine Tumor
Pfizer 106
Testing effectiveness (Phase 2)UnknownNCT01203306
What this trial is testing

Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Carcinomas
University of Turin, Italy 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595424
What this trial is testing

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Who this might be right for
Gastric Neuroendocrine CarcinomaIntestinal Neuroendocrine CarcinomaPancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research Group 67
Not applicableUnknownNCT03896958
What this trial is testing

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Who this might be right for
Cancer, All TypesCancer of LiverCancer of Stomach+42 more
SpeciCare 1,000
Early research (Phase 1)Not Yet RecruitingNCT07252661
What this trial is testing

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

Who this might be right for
Hepatocellular CarcinomaRenal Cell CarcinomaThyroid Carcinoma, Medullary+6 more
AccSalus Biosciences, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT01121562
What this trial is testing

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Who this might be right for
Pancreatic Neuroendocrine Tumors
Pfizer 12
Post-approval studies (Phase 4)Study completedNCT03289741
What this trial is testing

Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Who this might be right for
Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center 51
Early research (Phase 1)WithdrawnNCT02831179
What this trial is testing

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Who this might be right for
Functional Pancreatic Neuroendocrine TumorMalignant SomatostatinomaMerkel Cell Carcinoma+26 more
Vanderbilt-Ingram Cancer Center
Early research (Phase 1)Looking for participantsNCT06732505
What this trial is testing

A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens

Who this might be right for
Neuroendocrine Neoplasm
Peking University Cancer Hospital & Institute 36
Testing effectiveness (Phase 2)Study completedNCT03290079
What this trial is testing

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Cancer
H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Ended earlyNCT01648465
What this trial is testing

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

Who this might be right for
Gastrointestinal TumorsPancreatic TumorsGastrointestinal Neuroendocrine Tumors+1 more
Hellenic Cooperative Oncology Group 25
Testing effectiveness (Phase 2)Ended earlyNCT03630120
What this trial is testing

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, MedullaryDifferentiated Thyroid Cancer+3 more
H. Lee Moffitt Cancer Center and Research Institute 6
Testing effectiveness (Phase 2)Ended earlyNCT01215578
What this trial is testing

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Who this might be right for
Neuroendocrine TumorsPancreatic NeoplasmsAdvanced Disease+1 more
Assistance Publique - Hôpitaux de Paris 33
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Load More Results
40
116